Expressions of HSP90α and HSP90β in colorectal cancer tissues and their clinical significances

doi:10.3760/cma.j.cn371439-20211210-00052

Abstract

Abstract:

Objective To study the expressions of heat shock protein （HSP）90α and HSP90β in colorectal cancer and paracancer tissues, and to investigate the relationships between HSP90α, HSP90β and clinicopathological features of colorectal cancer patients, and to analyze their correlation. Methods The tumor tissues and paracancer tissues of 117 patients with colorectal cancer were selected from the Department of Gastrointestinal Surgery, Third Affiliated Hospital of Shandong First Medical University from January 2016 to December 2020. The expression levels of HSP90α and HSP90β were detected by immunohistochemistry, and the relationships between the two proteins and clinicopathological features and the correlation of their expressions were analyzed. Results The positive expression rates of HSP90α in colorectal cancer tissues and paracancer tissues were 74.4% （87/117） and 12.0% （14/117）, and there was a statistically significant difference （χ²=92.83, P<0.001）. The positive expression rate of HSP90β in colorectal cancer tissues and paracancer tissues was 61.5% （72/117） and 10.3% （12/117）, and there was a statistically significant difference （χ²=66.86, P<0.001）. The expression of HSP90α was correlated with tumor location （χ²=8.67, P=0.003）, vascular invasion （χ²=8.68, P=0.003）, lymph node metastasis （χ²=8.52, P=0.004）, T stage （χ²=21.07, P<0.001）, N stage （χ²=11.94, P=0.003）, M stage （χ²=5.37, P=0.020）, pathological stage （χ²=25.64, P<0.001）. The expression of HSP90β was correlated with lymph node metastasis （χ²=4.03, P=0.045）, T stage （χ²=11.09, P=0.007）, N stage （χ²=6.56, P=0.038）, M stage （χ²=12.43, P<0.001）, pathological stage （χ²=17.34, P=0.001）. There was a positive correlation between the expressions of the two proteins in colorectal cancer tissues （r=0.42, P<0.001）. Conclusion The expressions of HSP90α and HSP90β in colorectal cancer tissues are significantly higher than those in paracancer tissues, and they are related to lymph node metastasis and pathological stage. There is a positive correlation between the two proteins, which may be involved in the occurrence and development of colorectal cancer and are expected to become new tumor markers.

Key words: Colorectal neoplasms, HSP90α, HSP90β

Chen Cunbao, Lu Shoutang, Wang Ruogu, Yang Jianshu, Li Jianqi, Zhen Yanan, Xu Zhongfa. Expressions of HSP90α and HSP90β in colorectal cancer tissues and their clinical significances[J]. Journal of International Oncology, 2022, 49(5): 282-284.

Figures/Tables 3

References 9

[1]	Soleimani A, Zahiri E, Ehtiati S, et al. Therapeutic potency of heat-shock protein-70 in the pathogenesis of colorectal cancer: current status and perspectives[J]. Biochem Cell Biol, 2019, 97(2): 85-90. DOI: 10.1139/bcb-2018-0177. doi: 10.1139/bcb-2018-0177 pmid: 30273495
[2]	Yun CW, Kim HJ, Lim JH, et al. Heat shock proteins: agents of cancer development and therapeutic targets in anti-cancer therapy[J]. Cells, 2019, 9(1): 60. DOI: 10.3390/cells9010060. doi: 10.3390/cells9010060
[3]	Xiao X, Wang W, Li Y, et al. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma[J]. J Exp Clin Cancer Res, 2018, 37(1): 201. DOI: 10.1186/s13046-018-0880-6. doi: 10.1186/s13046-018-0880-6
[4]	Wu J, Liu T, Rios Z, et al. Heat shock proteins and cancer[J]. Trends Pharmacol Sci, 2017, 38(3): 226-256. DOI: 10.1016/j.tips.2016.11.009. doi: 10.1016/j.tips.2016.11.009
[5]	Saini J, Sharma PK. Clinical, prognostic and therapeutic significance of heat shock proteins in cancer[J]. Curr Drug Targets, 2018, 19(13): 1478-1490. DOI: 10.2174/1389450118666170823121248. doi: 10.2174/1389450118666170823121248
[6]	Yang S, Xiao H, Cao L. Recent advances in heat shock proteins in cancer diagnosis, prognosis, metabolism and treatment[J]. Biomed Pharmacother, 2021, 142: 112074. DOI: 10.1016/j.biopha.2021.112074. doi: 10.1016/j.biopha.2021.112074
[7]	Park Y, Lee KS, Park SY, et al. Potential prognostic value of histone deacetylase 6 and acetylated heat-shock protein 90 in early-stage breast cancer[J]. J Breast Cancer, 2015, 18(3): 249-255. DOI: 10.4048/jbc.2015.18.3.249. doi: 10.4048/jbc.2015.18.3.249
[8]	Huang T, Chen S, Han H, et al. Expression of Hsp90α and cyclin B1 were related to prognosis of esophageal squamous cell carcinoma and keratin pearl formation[J]. Int J Clin Exp Pathol, 2014, 7(4): 1544-1552.
[9]	Wu Y, Huang B, Liu Q, et al. Heat shock protein 90-β over-expression is associated with poor survival in stage Ⅰ lung adenocarcinoma patients[J]. Int J Clin Exp Pathol, 2015, 8(7): 8252-8259.

临床病理特征	例数	HSP90α 阳性	χ²值	P值	HSP90β 阳性	χ²值	P值
性别
男	66	49（74.2）	<0.01	0.974	40（60.6）	0.05	0.814
女	51	38（74.5）	<0.01	0.974	32（62.7）	0.05	0.814
年龄（岁）
<65	72	53(73.6）	0.06	0.815	43（59.7）	0.26	0.610
≥65	45	34（75.6）	0.06	0.815	29（64.4）	0.26	0.610
吸烟饮酒史
有	52	41（78.8）	0.99	0.320	34（65.4）	0.58	0.444
无	65	46（70.8）	0.99	0.320	38（58.5）	0.58	0.444
肿瘤位置
结肠	46	41（89.1）	8.67	0.003	31（67.4）	1.09	0.295
直肠	71	46（64.8）	8.67	0.003	41（57.7）	1.09	0.295
血管侵犯
有	32	30（93.8）	8.68	0.003	25（78.1）	2.43	0.119
无	85	57（67.1）	8.68	0.003	47（55.3）	2.43	0.119
神经侵犯
有	13	12（92.3）	2.47	0.116	9（69.2）	0.36	0.545
无	104	75（72.1）	2.47	0.116	63（60.6）	0.36	0.545
淋巴结转移
有	50	44（88.0）	8.52	0.004	36（72.0）	4.03	0.045
无	67	43（64.2）	8.52	0.004	36（53.7）	4.03	0.045
分化程度
高分化	0	0（0）	3.23	0.072	0（0）	1.03	0.369
中分化	105	75（71.4）			63（60.0）
低分化	12	12（100）			9（75.0）
T分期
T₁	4	1（25.0）	21.07	<0.001	1（25.0）	11.09	0.007
T₂	12	3（25.0）			4（33.3）
T₃	16	12（75.0）			7（43.8）
T₄	85	71（83.5）			60（70.6）
N分期
N₀	67	42（62.7）	11.94	0.003	35（52.2）	6.56	0.038
N₁	23	21（91.3）			15（65.2）
N₂	27	24（88.9）			22（81.5）
M分期
M₀	100	70（70.0）	5.37	0.020	55（55.0）	12.43	<0.001
M₁	17	17（100）	5.37	0.020	17（100）	12.43	<0.001
病理分期
Ⅰ	15	4（26.7）	25.64	<0.001	5（33.3）	17.34	0.001
Ⅱ	47	33（70.2）			25（53.2）
Ⅲ	38	33（86.8）			25（65.8）
Ⅳ	17	17（100）			17（100）

[1]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[6]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[7]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[8]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[9]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[10]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[11]	Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46.
[12]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang. Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 555-559.
[13]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang. Predictive value of inflammatory markers in colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 560-563.
[14]	Zhao Ying, Zhang Gehong. Study on the correlations between AGR, PLR and NLR changes and chemotherapy efficacy of metastatic colorectal cancer [J]. Journal of International Oncology, 2022, 49(8): 473-477.
[15]	Huang Mengpan, Wang Xuehong, Lu Yongfu. Mechanism of FOXA2 in colorectal cancer and its application in diagnosis and treatment [J]. Journal of International Oncology, 2022, 49(8): 490-493.